FDA Designates Antifungal Agent QDIP Status

Astellas announced that the FDA has designated isavuconazole as a Qualified Infectious Disease Product (QDIP) for the treatment of invasive candidiasis.

Isavuconazole is an investigational once-daily intravenous and oral broad-spectrum antifungal being developed for the treatment of severe invasive and life-threatening fungal infections.

RELATED: Isavuconazole NDA Submitted for Invasive Fungal Infections

Previously in February, the FDA designated isavuconazole as a Qualified Infectious Disease Product (QIDP) for invasive mucormycosis. QIDP designation for the treatment of invasive aspergillosis was granted last year. Also, in 2013, isavuconazole was granted Orphan Drug status for invasive aspergillosis and invasive mucormycosis.

For more information call (877) 829-7942 or visit Astellas.com.

Loading links....